IL294961A - Bicyclic ketone compounds and methods of using them - Google Patents

Bicyclic ketone compounds and methods of using them

Info

Publication number
IL294961A
IL294961A IL294961A IL29496122A IL294961A IL 294961 A IL294961 A IL 294961A IL 294961 A IL294961 A IL 294961A IL 29496122 A IL29496122 A IL 29496122A IL 294961 A IL294961 A IL 294961A
Authority
IL
Israel
Prior art keywords
phenyl
dihydro
pyrrolo
mmol
fluoro
Prior art date
Application number
IL294961A
Other languages
English (en)
Hebrew (he)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL294961A publication Critical patent/IL294961A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
IL294961A 2017-07-14 2018-07-12 Bicyclic ketone compounds and methods of using them IL294961A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762532767P 2017-07-14 2017-07-14
PCT/EP2018/068998 WO2019012063A1 (en) 2017-07-14 2018-07-12 BICYCLIC KETONIC COMPOUNDS AND METHODS OF USE

Publications (1)

Publication Number Publication Date
IL294961A true IL294961A (en) 2022-09-01

Family

ID=62916677

Family Applications (2)

Application Number Title Priority Date Filing Date
IL271981A IL271981B (en) 2017-07-14 2018-07-12 Bicyclic ketone compounds and methods of using them
IL294961A IL294961A (en) 2017-07-14 2018-07-12 Bicyclic ketone compounds and methods of using them

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL271981A IL271981B (en) 2017-07-14 2018-07-12 Bicyclic ketone compounds and methods of using them

Country Status (30)

Country Link
US (3) US11098058B2 (OSRAM)
EP (2) EP4397309A3 (OSRAM)
JP (2) JP7258843B2 (OSRAM)
KR (2) KR102664604B1 (OSRAM)
CN (2) CN119613408A (OSRAM)
AR (1) AR112274A1 (OSRAM)
AU (3) AU2018300043B2 (OSRAM)
BR (1) BR112020000771A2 (OSRAM)
CA (2) CA3067944C (OSRAM)
CL (1) CL2020000101A1 (OSRAM)
CO (1) CO2020000134A2 (OSRAM)
CR (1) CR20200002A (OSRAM)
DK (1) DK3652178T3 (OSRAM)
ES (1) ES2973661T3 (OSRAM)
FI (1) FI3652178T3 (OSRAM)
HR (1) HRP20240354T1 (OSRAM)
HU (1) HUE065793T2 (OSRAM)
IL (2) IL271981B (OSRAM)
LT (1) LT3652178T (OSRAM)
MA (1) MA49560B1 (OSRAM)
PE (1) PE20200793A1 (OSRAM)
PH (1) PH12020500105A1 (OSRAM)
PL (1) PL3652178T3 (OSRAM)
PT (1) PT3652178T (OSRAM)
RS (1) RS65308B1 (OSRAM)
SG (1) SG11202000333UA (OSRAM)
SI (1) SI3652178T1 (OSRAM)
TW (1) TWI805595B (OSRAM)
UA (1) UA125448C2 (OSRAM)
WO (1) WO2019012063A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201831478A (zh) * 2016-12-02 2018-09-01 瑞士商赫孚孟拉羅股份公司 雙環醯胺化合物及其使用方法
EP4397309A3 (en) 2017-07-14 2024-09-04 F. Hoffmann-La Roche AG Bicyclic ketone compounds and methods of use thereof
EP3704097B1 (en) 2017-10-31 2023-10-25 F. Hoffmann-La Roche AG Bicyclic sulfones and sulfoxides and methods of use thereof
JP7585205B2 (ja) 2019-01-11 2024-11-18 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二環式ピロロトリアゾールケトン化合物及びその使用方法
WO2021198981A1 (en) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Antiviral compounds and uses thereof
JP7677584B2 (ja) * 2020-04-27 2025-05-15 オートタック インコーポレーテッド Ｕｂｒボックスドメインリガンドとしての化合物
CA3214802A1 (en) 2021-04-02 2022-10-06 Genentech, Inc. Processes for making bicyclic ketone compounds
WO2023039795A1 (zh) * 2021-09-16 2023-03-23 维泰瑞隆（北京）生物科技有限公司 Rip1激酶抑制剂及其用途
EP4526300A1 (en) * 2022-05-19 2025-03-26 Merck Sharp & Dohme LLC Ripk1 inhibitors and methods of use
WO2024260932A2 (en) * 2023-06-19 2024-12-26 F. Hoffmann-La Roche Ag Process for the preparation of a chiral pyrrolo triazole alcohol

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620508A1 (de) 1965-07-23 1969-09-18 Thomae Gmbh Dr K Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3948903A (en) 1972-12-15 1976-04-06 Parke, Davis & Company Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8610530D0 (en) 1986-04-30 1986-06-04 Fbc Ltd Herbicides
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
JPH07509250A (ja) 1992-07-27 1995-10-12 アメリカ合衆国 血液脳バリヤーへのリポソームの標的化
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
AU8071698A (en) 1997-06-13 1998-12-30 Sugen, Inc. Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction
CA2399791A1 (en) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
WO2002017930A2 (en) 2000-08-30 2002-03-07 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
JP4494205B2 (ja) 2002-08-26 2010-06-30 武田薬品工業株式会社 カルシウム受容体調節化合物およびその用途
EP1581186A2 (en) 2002-12-03 2005-10-05 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
TW200509910A (en) 2003-05-02 2005-03-16 Elan Pharm Inc Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
WO2005025511A2 (en) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
JP2008539220A (ja) 2005-04-26 2008-11-13 ファイザー・リミテッド バソプレシンアンタゴニストとしてのトリアゾール誘導体
EP2083009A1 (de) 2008-01-22 2009-07-29 Grünenthal GmbH Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN101824036A (zh) 2009-03-05 2010-09-08 上海恒瑞医药有限公司 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
AR077463A1 (es) 2009-07-09 2011-08-31 Irm Llc Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias
WO2013067260A1 (en) 2011-11-03 2013-05-10 Genentech, Inc. Bicyclic piperazine compounds
CA2871695A1 (en) 2012-05-22 2013-11-28 F. Hoffmann-La Roche Ag Substituted dipyridylamines and uses thereof
WO2014111496A1 (en) 2013-01-18 2014-07-24 F. Hoffmann-La Roche Ag 3-substituted pyrazoles and use as dlk inhibitors
TWI648273B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類（三）
WO2014177060A1 (en) 2013-05-01 2014-11-06 F.Hoffmann-La Roche Ag Biheteroaryl compounds and uses thereof
KR20160002850A (ko) 2013-05-01 2016-01-08 에프. 호프만-라 로슈 아게 C-연결된 헤테로사이클로알킬 치환된 피리미딘 및 이의 용도
ES2780699T3 (es) 2013-07-10 2020-08-26 Vertex Pharma Amidas de piperidina fusionadas útiles como moduladores de canales iónicos
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
JP6554481B2 (ja) 2014-03-26 2019-07-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ オートタキシン（ａｔｘ）及びリゾホスファチジン酸（ｌｐａ）産生の阻害剤としての縮合［１，４］ジアゼピン化合物
US20170266199A1 (en) 2014-08-21 2017-09-21 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
WO2016128908A1 (en) * 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2016142310A1 (en) 2015-03-09 2016-09-15 F. Hoffmann-La Roche Ag Tricyclic dlk inhibitors and uses thereof
CA2988601C (en) * 2015-07-02 2021-12-07 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
WO2017096301A1 (en) 2015-12-04 2017-06-08 Denali Therapeutics Inc. Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (ripk 1)
US10961258B2 (en) 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
EA201891620A1 (ru) 2016-02-05 2019-02-28 Денали Терапьютикс Инк. Ингибиторы взаимодействующей с рецептором протеинкиназы 1
TW201831478A (zh) 2016-12-02 2018-09-01 瑞士商赫孚孟拉羅股份公司 雙環醯胺化合物及其使用方法
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
CN110169087B (zh) 2017-01-05 2021-04-20 微软技术许可有限责任公司 重定向音频输出
EP4397309A3 (en) 2017-07-14 2024-09-04 F. Hoffmann-La Roche AG Bicyclic ketone compounds and methods of use thereof
BR112020007067A2 (pt) 2017-10-11 2020-10-06 F. Hoffmann-La Roche Ag compostos bicíclicos para uso como inibidores rip1 quinase
EP3704097B1 (en) 2017-10-31 2023-10-25 F. Hoffmann-La Roche AG Bicyclic sulfones and sulfoxides and methods of use thereof

Also Published As

Publication number Publication date
CA3185865A1 (en) 2019-01-17
SG11202000333UA (en) 2020-02-27
AU2018300043B2 (en) 2021-04-01
CA3067944C (en) 2023-03-14
JP7734163B2 (ja) 2025-09-04
US20210139504A1 (en) 2021-05-13
EP4397309A3 (en) 2024-09-04
US20240300974A1 (en) 2024-09-12
SI3652178T1 (sl) 2024-05-31
RS65308B1 (sr) 2024-04-30
US20190100530A1 (en) 2019-04-04
BR112020000771A2 (pt) 2020-07-14
PT3652178T (pt) 2024-03-18
CL2020000101A1 (es) 2020-07-17
KR20240065201A (ko) 2024-05-14
LT3652178T (lt) 2024-04-10
EP3652178B1 (en) 2024-01-24
CA3067944A1 (en) 2019-01-17
JP7258843B2 (ja) 2023-04-17
EP3652178A1 (en) 2020-05-20
PL3652178T3 (pl) 2024-05-06
CO2020000134A2 (es) 2020-01-17
TW201920149A (zh) 2019-06-01
AU2018300043A1 (en) 2020-01-16
CN110914271A (zh) 2020-03-24
TWI805595B (zh) 2023-06-21
WO2019012063A1 (en) 2019-01-17
JP2023085449A (ja) 2023-06-20
PH12020500105A1 (en) 2020-11-09
RU2020106375A (ru) 2021-08-16
KR20200030558A (ko) 2020-03-20
US11834461B2 (en) 2023-12-05
IL271981B (en) 2022-09-01
EP4397309A2 (en) 2024-07-10
DK3652178T3 (da) 2024-03-25
CN110914271B (zh) 2024-12-10
IL271981A (en) 2020-02-27
ES2973661T3 (es) 2024-06-21
MA49560A (fr) 2020-05-20
AU2021204369A1 (en) 2021-07-29
MA49560B1 (fr) 2024-05-31
US11098058B2 (en) 2021-08-24
CR20200002A (es) 2020-02-10
AR112274A1 (es) 2019-10-09
HRP20240354T1 (hr) 2024-06-07
AU2023203292A1 (en) 2023-06-22
FI3652178T3 (fi) 2024-03-19
NZ760749A (en) 2024-08-30
JP2020526549A (ja) 2020-08-31
CN119613408A (zh) 2025-03-14
RU2020106375A3 (OSRAM) 2022-03-25
UA125448C2 (uk) 2022-03-09
PE20200793A1 (es) 2020-08-10
HUE065793T2 (hu) 2024-06-28
AU2023203292B2 (en) 2025-01-30
KR102664604B1 (ko) 2024-05-14

Similar Documents

Publication Publication Date Title
AU2023203292B2 (en) Bicyclic ketone compounds and methods of use thereof
EP3781571B1 (en) N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
US11607396B2 (en) Bicyclic amide compounds and methods of use thereof
WO2019086494A1 (en) Bicyclic sulfones and sulfoxides and methods of use thereof
AU2018348930A1 (en) Bicyclic compounds for use as RIP 1 kinase inhibitors
US20250282788A1 (en) Bicyclic ketone compounds and methods of use thereof
RU2797922C2 (ru) Бициклические кетоны и способы их применения
HK40062362A (en) Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof
HK40062362B (en) Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof
HK40017913B (zh) 二环酮化合物及其使用方法